Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Steel Pipe Industry of Indonesia Plans IDR 150 Billion Share Buyback

Steel Pipe Industry of Indonesia Plans IDR 150 Billion Share Buyback

BitgetBitget2026/11/05 01:38
  • Steel Pipe Industry of Indonesia announced a planned IDR 150 billion share buyback, excluding brokerage fees and related costs.
  • The program targets approximately 250,000,000 shares, representing 3.48% of issued shares.
  • Repurchases will run following the November 5, 2026 disclosure through February 5, 2027.
  • Purchases will be capped at IDR 600 per share, funded entirely from internal cash.
  • The company considers its shares undervalued relative to performance; repurchased shares will be held as treasury stock.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Steel Pipe Industry of Indonesia Tbk published the original content used to generate this news brief via Indonesia Stock Exchange (IDX) (Ref. ID: 32182114) on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12